6-K

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF A FOREIGN ISSUER

PURSUANT TO RULE 13A-16 OR 15D-16

OF THE SECURITIES EXCHANGE ACT OF 1934

For October 16, 2013

ASML Holding N.V.

De Run 6501

5504 DR Veldhoven

The Netherlands

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  x            Form 40-F  ¨

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  ¨             No  x

If ‘‘Yes’’ is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b):

EXCEPT FOR REFERENCES TO “NET BOOKINGS, EXCLUDING EUV” AND “SYSTEM BACKLOG, EXCLUDING EUV,” EXHIBITS 99.1, 99.3 AND 99.4 TO THIS REPORT ON FORM 6-K ARE INCORPORATED BY REFERENCE IN THE REGISTRATION STATEMENT ON S-8 (FILE NO. 333-13332), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-105600), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-109154), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-116337), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-126340), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-136362), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-141125), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-142254), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-144356), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-147128), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-153277), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-162439), THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-170034),THE REGISTRATION STATEMENT ON FORM S-8 (FILE NO. 333-188938) OF ASML HOLDING N.V.

Exhibits

99.1	“ASML confirms 2013 outlook and sees H2 2013 sales levels continuing in H1 2014,” press release dated October 16, 2013
99.2	“ASML confirms 2013 outlook and sees H2 2013 sales levels continuing in H1 2014,” presentation dated October 16, 2013
99.3	Summary U.S. GAAP Consolidated Financial Statements
99.4	Summary IFRS Consolidated Financial Statements

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	ASML HOLDING N.V. (Registrant)
Date: October 16, 2013	By:	/s/ Peter T.F.M. Wennink
		Peter T.F.M. Wennink President and Chief Executive Officer

3

EX-99.1

Exhibit 99.1

Media Relations Contacts

Lucas van Grinsven - Corporate Communications - +31 40 268 3949 - Veldhoven, the Netherlands

Investor Relations Contacts

Craig DeYoung - Investor Relations - +1 480 696 2762 - Chandler, Arizona, USA

Franki D’Hoore - Investor Relations - +31 40 268 6494 - Veldhoven, the Netherlands

ASML confirms 2013 outlook and sees H2 2013 sales levels continuing in H1 2014

VELDHOVEN, the Netherlands, 16 October 2013 - ASML Holding N.V. (ASML) today publishes 2013 third-quarter results.

• ASML reports Q3 2013 results as guided and confirms a 2013 full year net sales outlook of up to EUR 5.2 billion, including Cymer

• ASML guides fourth-quarter net sales at around EUR 1.8 billion, gross margin at between 43 and 44 percent, including accounting impact from Cymer acquisition

• ASML sees H1 2014 sales at similar levels to H2 2013, excluding EUV

(Figures in millions of euros unless otherwise indicated)	Q3 2013		Q2 2013
Net sales		1,318		1,187
of which service and field option sales		359		271
Other income (Co-Investment Program)		17		16
New systems sold (units)		30		34
Used systems sold (units)		4		4
Net bookings, excluding EUV		1,415		1,065
Net bookings, excluding EUV (units)		51		38
ASP of booked systems, excluding EUV		27.7		28.0
Systems backlog, excluding EUV		1,838		1,395
Systems backlog, excluding EUV (units)		59		42
Gross profit		531		482
Gross margin (%)		40.3		40.6
Net income		193		221
EPS (in euro)		0.44		0.52
End-quarter cash and cash equivalents and short-term investments		2,724		2,351

CEO Statement

“ASML’s third-quarter sales and gross margin are in line with our previous guidance and were mainly driven by sales to logic customers, who continue to place orders as they fulfill their lithography capacity and technology needs with our leading-edge immersion scanners and Holistic Lithography products that are growing towards 10 percent of sales. Our first TWINSCAN NXT:1970Ci was shipped in the quarter. It delivers record productivity of above 250 wafers per hour and is optimally suited to multiple patterning at the 20/14 nanometer node, supporting our customers’ cost and technology roadmaps. As expected, we have seen healthy bookings for our advanced products from memory customers, driven by DRAM technology upgrades and additional NAND capacity. Therefore, we see demand in the first half of 2014 at a level consistent with our H2 2013 net sales, excluding additional Extreme Ultraviolet (EUV) system sales which are incremental until insertion into volume production. The integration work on our NXE:3300B EUV scanners is progressing steadily. We remain on target to deliver systems with a throughput of 70 wafers per hour next year, upgradeable to 125 wafers per hour in 2015. Based on the progress over the last few quarters, customers have intensified their cooperation with us, allocating investments and resources focused on potential insertion of EUV at the 10nm logic node,” said ASML President and Chief Executive Officer Peter Wennink.

Third Quarter 2013 Product Highlights

• Our new TWINSCAN NXT:1970Ci system offers overlay below 2 nanometers, focus control of less than 20 nanometers and productivity of more than 250 wafers per hour. About 250 TWINSCAN NXT:1950i and NXT:1960Bi systems currently in use by our customers are field-upgradeable to the same performance level.

• We have shipped the 100^th YieldStar metrology system, which generates data for our Holistic Lithography products that control overlay, CD and focus for the most advanced process nodes of our customers.

• We are installing the first NXE:3300B systems at customer sites and plan to ship a total of three systems this year.

• In imaging tests, the NXE:3300B met the production requirements of the 10 nanometer logic node in imaging of lines and spaces and other critical exposure features, and it will be extendable to the 7 nanometer logic node.

Outlook

• For the fourth quarter of 2013, ASML expects net sales of around EUR 1.8 billion, a gross margin of 43-44 percent, R&D costs of about EUR 255 million, other income of EUR 17 million — which consists of contributions from participants of the Customer Co-Investment Program — and SG&A costs of about EUR 90 million.

• The expected fourth-quarter gross margin of between 43 and 44 percent includes an impact from non-cash purchase price accounting adjustments related to the Cymer acquisition, equivalent to a gross margin impact of about 1.6 percentage points.

2

• In the fourth quarter we expect to recognize revenue for one of the three NXE:3300B EUV systems that we expect to ship this year. The first series of such systems will not contribute to profit due to the low utilization of our EUV manufacturing infrastructure and early learning curve costs in our supply chain and, directly resulting from the Cymer acquisition, the cost of the liability to upgrade the first 11 EUV sources in the field, which is now assumed by ASML. Excluding the one NXE:3300B, the Q4 gross margin would be 1.6 percent higher.

Update Share Buy Back Program

As part of ASML’s policy to return excess cash to shareholders through dividend and regularly timed share buy-backs, ASML has announced its intention to purchase up to EUR 1.0 billion of its own shares within the 2013-2014 timeframe. Through 30 September 2013, ASML has acquired 2.2 million shares under this program for total consideration of EUR 136.3 million. The repurchased shares will be cancelled. All transactions under the buy-back programs are published on ASML’s website (www.asml.com/investors). The share buy-back program may be suspended, modified or discontinued at any time.

About ASML

ASML makes possible affordable microelectronics that improve the quality of life. ASML invents and develops complex technology for high-tech lithography machines for the semiconductor industry. ASML’s guiding principle is continuing Moore’s Law towards ever smaller, cheaper, more powerful and energy-efficient semiconductors. Our success is based on three pillars: technology leadership combined with customer and supplier intimacy, highly efficient processes and entrepreneurial people. We are a multinational company with over 70 locations in 16 countries, headquartered in Veldhoven, the Netherlands. We employ more than 13,000 people on payroll and flexible contracts (expressed in full time equivalents). Our company is an inspiring place where employees work, meet, learn and share. ASML is traded on Euronext Amsterdam and NASDAQ under the symbol ASML. More information about ASML, our products and technology, and career opportunities is available on: www.asml.com

Investor and Media Conference Call

A conference call for investors and media will be hosted by CEO Peter Wennink at 15:00 PM Central European Time / 09:00 AM Eastern U.S. time. Dial-in numbers are: in the Netherlands + 31 20 794 8484 and the US + 1 480 629 9856 (no confirmation code needed). Listen-only access is also available via www.asml.com

A replay of the Investor and Media Call will be available on www.asml.com

3

US GAAP and IFRS Financial Reporting

ASML’s primary accounting standard for quarterly earnings releases and annual reports is US GAAP, the accounting principles generally accepted in the United States of America. Quarterly US GAAP consolidated statements of operations, consolidated statements of cash flows and consolidated balance sheets, and a reconciliation of net income and equity from US GAAP to IFRS as adopted by the EU (‘IFRS’)are available on www.asml.com

In addition to reporting financial figures in accordance with US GAAP, ASML also reports financial figures in accordance with IFRS for statutory purposes. The most significant differences between US GAAP and IFRS that affect ASML concern the capitalization of certain product development costs, the accounting of share-based payment plans and the accounting of income taxes. ASML’s quarterly IFRS consolidated statement of profit or loss, consolidated statement of cash flows, consolidated statement of financial position and a reconciliation of net income and equity from US GAAP to IFRS are available on www.asml.com

The consolidated balance sheets of ASML Holding N.V. as of 29 September 2013, the related consolidated statements of operations and consolidated statements of cash flows for the quarter ended 29 September 2013 as presented in this press release are unaudited.

Regulated Information

This press release, the US GAAP consolidated financial statements and the IFRS consolidated financial statements published on www.asml.com comprise regulated information within the meaning of the Dutch Financial Markets Supervision Act (Wet op het financieel toezicht).

4

Forward Looking Statements

“Safe Harbor” Statement under the US Private Securities Litigation Reform Act of 1995: the matters discussed in this document may include forward-looking statements, including statements made about our outlook, expected sales levels, realization of systems backlog, IC unit demand, expected financial results, gross margin and expenses, expected impact and adjustments relating to the Cymer acquisition (including purchase price allocation adjustments), the number of EUV systems expected to be shipped and recognized in revenue and timing of shipments, dividend policy and intention to repurchase shares. These forward looking statements are subject to risks and uncertainties including, but not limited to: economic conditions, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), including the impact of general economic conditions on consumer confidence and demand for our customers’ products, competitive products and pricing, the impact of manufacturing efficiencies and capacity constraints, the continuing success of technology advances and the related pace of new product development and customer acceptance of new products, our ability to enforce patents and protect intellectual property rights, the risk of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, changes in exchange rates, available cash, distributable reserves for dividend payments and share repurchases, our ability to successfully integrate Cymer and the amounts of adjustments ultimately recognized in connection with the Cymer acquisition, and other risks indicated in the risk factors included in ASML’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission.

5

EX-99.2

Exhibit 99.2

Veldhoven, the Netherlands October 16, 2013 ASML confirms 2013 outlook and sees H2 2013 sales levels continuing in H1 2014 ASML 2013 Third Quarter Results

Forward looking statements "Safe Harbor" Statement under the US Private Securities Litigation Reform Act of 1995: the matters discussed in this document may include forward-looking statements, including statements made about our outlook, expected sales levels, realization of systems backlog, IC unit demand, expected financial results, gross margin and expenses, expected impact and adjustments relating to the Cymer acquisition (including purchase price allocation adjustments), the number of EUV systems expected to be shipped and recognized in revenue and timing of shipments, dividend policy and intention to repurchase shares. These forward looking statements are subject to risks and uncertainties including, but not limited to: economic conditions, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), including the impact of general economic conditions on consumer confidence and demand for our customers' products, competitive products and pricing, the impact of manufacturing efficiencies and capacity constraints, the continuing success of technology advances and the related pace of new product development and customer acceptance of new products, our ability to enforce patents and protect intellectual property rights, the risk of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, changes in exchange rates, available cash, distributable reserves for dividend payments and share repurchases, our ability to successfully integrate Cymer and the amounts of adjustments ultimately recognized in connection with the Cymer acquisition, and other risks indicated in the risk factors included in ASML's Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission. 16 October 2013 Public Slide 2

Business summary Business environment ASML technology status Outlook 16 October 2013 Public Slide 3

Business summary 16 October 2013 Public Slide 4

Net system sales breakdown in value: Q3 2013 Total value is € 959 million Technology (CHART) I-Line 1% ArF Immersion 88% KrF 11% (CHART) Korea 39% Taiwan 51% USA 1% Region (CHART) Foundry 60% Memory 38% IDM 2% End-Use (CHART) Sales in Units 20 10 4 16 October 2013 Public Slide 5 Numbers have been rounded for readers' convenience Europe 5% Rest of Asia 4%

Q3 results - highlights Net sales of € 1,318 million, 34 litho systems sold, valued at € 959 million, net service and field option sales at € 359 million Gross margin of 40.3% Amongst others, including 3.3% inventory fair value adjustment Cymer acquisition Operating margin of 16.1% Net bookings of € 1,415 million, 51 systems Backlog at € 1,838 million, 59 systems Net bookings and backlog numbers are excluding EUV Numbers have been rounded for readers' convenience . 16 October 2013 Public Slide 6

(CHART) Total net sales M€ 3,768 Numbers have been rounded for readers' convenience 2,954 1,596 4,508 5,651 16 October 2013 Q1 Q2 Q3 Q4 Slide 7 4,732 Public

Q2 13 Q3 13 Net sales 1,187 1,318** Gross profit 482 531 Gross margin % 40.6% 40.3% Other income (CCIP*) 16 17 R&D costs (200) (244) SG&A costs (68) (91) Income from operations 230 212 Operating income % 19.4% 16.1% Net income 221 193 Net income as a % of net sales 18.6% 14.7% Earnings per share (basic) € 0.52 0.44 Consolidated statements of operations M€ Numbers have been rounded for readers' convenience 16 October 2013 Public Slide 8 * Customer Co-Investment Program ** No CCIP contribution this quarter

Key financial trends 2012 - 2013 Consolidated statements of operations M€ Numbers have been rounded for readers' convenience Q3 12 Q4 12 Q1 13 Q2 13 Q3 13 Net sales 1,229 1,023 892 1,187 1,318 Gross profit 531 420 341 482 531 Gross margin % 43.2% 41.1% 38.2% 40.6% 40.3% R&D costs (144) (155) (185) (200) (244) SG&A costs (70) (80) (63) (68) (91) Income from operations 317 185 107 230 212 Operating income % 25.8% 18.1% 12.1% 19.4% 16.1% Net income 275 298 96 221 193 Net income as a % of net sales 22.4% 29.1% 10.8% 18.6% 14.7% Litho units sold 40 34 29 38 34 ASP new litho systems 28.8 27.3 26.6 25.8 31.5 Net booking value 831 667 715 1,065 1,415 16 October 2013 Public Slide 9

Balance sheets M€ Numbers have been rounded for readers' convenience Assets Jun 30st, 2013 Sep 29st, 2013 Cash & cash equivalents and short-term investments 2,351 23% 2,724 25% Net accounts receivable and finance receivables 883 8% 1,070 10% Inventories, net 2,359 23% 2,480 22% Other assets 584 6% 674 6% Tax assets 264 2% 251 2% Fixed assets 3,937 38% 3,868 35% Total assets 10,378 100% 11,067 100% Liabilities and shareholders' equity Current liabilities 2,490 24% 2,758 25% Non-current liabilities 1,390 13% 1,706 15% Shareholders' equity 6,498 63% 6,603 60% Total liabilities and shareholders' equity 10,378 100% 11,067 100% 16 October 2013 Public Slide 10

Cash flows M€ Numbers have been rounded for readers' convenience Q2 13 Q3 13 Net income 221 193 Adjustments to reconcile net income to net cash flows from operating activities: Impairment and obsolescence 36 49 Depreciation and amortization 49 68 Deferred income taxes 15 (13) Other non-cash items 10 20 Change in assets and liabilities 150 (210) Net cash provided by (used in) operating activities 481 107 Net cash provided by (used in) investing activities (373) 41 Net cash provided by (used in) financing activities (294) 325 Total FX effects (2) (4) Net increase (decrease) in cash & cash equivalents (188) 469 16 October 2013 Public Slide 11

Bookings activity by sector, EUV not included Total value M€ 1,415 Net booked 49 new tools at € 1,409 million 2 used tools at € 6 million Numbers have been rounded for readers' convenience 16 October 2013 Public Slide 12 (CHART) Memory 42% IDM 26% Foundry 32%

Backlog in value per Sep 29th, EUV not included Total value M€ 1,838 Numbers have been rounded for readers' convenience 80% of backlog carries shipment dates in the next 6 months 16 October 2013 Public Slide 13 Technology (CHART) ArF immersion 77% KrF 19% ArF dry 4% (CHART) End-use Foundry 29% Memory 35% IDM 36% (CHART) Region (ship to location) USA 31% Korea 32% Taiwan 24% Rest of Asia 1% Europe 6% China 6% New systems Used systems Total systems Units 54 5 59 Value M€ 1,808 30 1,838 ASP M€ 33.5 6.0 31.1

Capital return to shareholders 16 October 2013 Public Slide 14 Through 30 September 2013, ASML acquired 2.2 million shares for a total consideration of € 136.3 million. The repurchased shares will be cancelled 14% of the announced € 1.0 billion 2013-2014 buy back program has been executed The company has returned more than € 4 billion in dividend and share buy backs since 2006

Business environment 16 October 2013 Public Slide 15

Business environment Foundry and Logic customers continue to place orders for our advanced tools to enable volume manufacturing of their next generation 14-16-20 nm devices We have also seen healthy bookings from memory customers, driven by DRAM technology upgrades and additional NAND capacity ASML sees H1 2014 sales at similar levels to H2 2013 (excluding EUV) 16 October 2013 Public Slide 16

ASML technology status 16 October 2013 Public Slide 17

Q3 product highlights Our new TWINSCAN NXT:1970Ci system offers overlay below 2 nm, focus control at less than 20 nm and productivity of more than 250 wafers per hours About 250 TWINSCAN NXT:1950i and NXT:1960Bi systems currently in use by our customers are field-upgradeable to the NXT:1970Ci performance level We have shipped the 100th YieldStar metrology system, which generates data for our Holistic Lithography products that control overlay, CD and focus for the most advanced process nodes of our customers Holistic litho products are growing towards 10% of net sales 16 October 2013 Public Slide 18

New generation NXT:1970Ci is now shipping Productivity 250 wafers per hour Improvements effect various aspects of system performance 16 October 2013 Public Slide 19 Overlay Imaging/Focus Defectivity Productivity Legend: knife for low defects Immersion hood Lens UV level sensor Wafer table PARIS sensor Wafer stage Wafer handler

ArFi roadmap enables smooth transition to EUV As well as supporting multiple patterning requirements until at least 2018 Public Slide 20 NXT:1950i NXT:1960Bi NXT:1970Ci Timing Q4 2011 Q1 2013 1H 2014 Overlay DCO / MMO 2.5 / 5.5nm 2.5 / 4.5nm 2.0 / 3.5nm Full Wafer Focus Unif 30nm 22nm 20nm Full Wafer CDU (iso) 3.0nm 2.0nm 1.3nm Throughput (96 shots) 190 WpH 230 WpH 250 WpH Defects/Wafer 10 10 <7 2010 - 2012 2013 - 2014 2014 - 2015 2016 - 2020 16 October 2013 Successors

NXT platform solidly established as factory workhorse Peak performance in excess of 5000 wafers per day Best wafers per day (CHART) Wafers per day 16 October 2013 Public Slide 21

(CHART) YieldStar metrology in volume production Shipped more than 100 systems to date 16 October 2013 Public Slide 22

EUV update Integration work on our NXE:3300B EUV scanners is progressing steadily We are installing the first NXE:3300B systems at customer sites We remain on target to deliver systems with a throughput of 70 wafers per hour in 2014, subsequently upgradeable to 125 wafers per hour in 2015 Based upon current system performance, customers have intensified their cooperation with us, allocating investments and resources focused on potential insertion of EUV at the 10nm logic node We plan to ship a total of 3 EUV systems this year 16 October 2013 Public Slide 23

EUV best solution for cost effective shrink in future (CHART) FinFET: no cost reduction Double patterning Limited scope for cost reduction on ArFi due to multiple patterning Single expose EUV best option for cost reduction ArFi EUV " 16 October 2013 Public Slide 24

Current EUV imaging performance meet production requirements of the 10 nm and it will be extendable to the 7 nm logic node Public Slide 25 ArFi Imaging 75nm 50nm 22nm 31nm ArFi (Double patterning) 16nm Node ? 1st insertion point for EUV Current EUV Imaging (Single Exposure) Industry requirements 16 October 2013

Outlook 16 October 2013 Public Slide 26

Q4 outlook Net sales about € 1.8 billion Gross margin 43 - 44% R&D costs of about € 255 million SG&A costs of about € 90 million (including approx. € 10 million restructuring charges ending Q4) Other income (Customer Co-Investment Program) of € 17 million Q4 gross margin includes: Non-cash purchase price accounting adjustments related to Cymer acquisition (1.6% GM impact) Revenue recognition for 1 NXE:3300B EUV system. The first systems will not contribute to profit due to low utilization of our EUV manufacturing infrastructure, early learning curve costs in our supply chain and the cost of the liability to upgrade the first 11 EUV sources in the field, resulting from the Cymer acquisition which is now assumed by ASML. Excluding the 1 EUV, the Q4 gross margin would be 1.6 % higher Pending enacting of the Dutch legislation, cost might increase € 6 -10 million due to a re-introduction of the crisis levy Public Slide 27 16 October 2013 ASML reiterates 2013 sales outlook of up to € 5.2 billion

EX-99.3

Exhibit 99.3

ASML—Summary U.S. GAAP Consolidated Statements of Operations ^1,2

	Three months ended,						Nine months ended,
(in millions EUR, except per share data)	Sep 29, 2013			Sep 30, 2012			Sep 29, 2013			Sep 30, 2012
Net system sales		959.5			1,000.3			2,551.9			3,035.1
Net service and field option sales		358.7			228.5			845.1			673.3
Total net sales		1,318.2			1,228.8			3,397.0			3,708.4
Total cost of sales		(787.4	)		(697.8	)		(2,043.3	)		(2,123.4	)
Gross profit		530.8			531.0			1,353.7			1,585.0
Other income		16.7			—			47.2			—
Research and development costs		(244.1	)		(143.8	)		(628.9	)		(433.7	)
Selling, general and administrative costs		(91.2	)		(69.7	)		(221.7	)		(179.8	)
Income from operations		212.2			317.5			550.3			971.5
Interest and other, net		(11.6	)		(2.5	)		(20.9	)		(2.8	)
Income before income taxes		200.6			315.0			529.4			968.7
Benefit from (provision for) income taxes		(7.5	)		(40.3	)		(19.3	)		(120.1	)
Net income		193.1			274.7			510.1			848.6
Basic net income per ordinary share		0.44			0.65			1.20			2.05
Diluted net income per ordinary share 3		0.43			0.65			1.19			2.03
Weighted average number of ordinary shares used in computing per share amounts (in millions):
Basic		443.0			422.5			425.6			414.6
Diluted 3		447.1			425.7			429.6			417.6

ASML—Ratios and Other Data ^1,2

	Three months ended,				Nine months ended,
(in millions EUR, except otherwise indicated)	Sep 29, 2013		Sep 30, 2012		Sep 29, 2013		Sep 30, 2012
Gross profit as a percentage of net sales		40.3		43.2		39.8		42.7
Income from operations as a percentage of net sales		16.1		25.8		16.2		26.2
Net income as a percentage of net sales		14.7		22.4		15.0		22.9
Income taxes as a percentage of income before income taxes		3.7		12.8		3.6		12.4
Shareholders’ equity as a percentage of total assets		59.7		65.2		59.7		65.2
Sales of systems (in units)		34		40		101		136
Average selling price of system sales (EUR millions)		28.2		25.0		25.3		22.3
Value of systems backlog excluding EUV (EUR millions)		1,838		1,340		1,838		1,340
Systems backlog excluding EUV (in units)		59		48		59		48
Average selling price of systems backlog excluding EUV (EUR millions)		31.1		27.9		31.1		27.9
Value of booked systems excluding EUV (EUR millions)		1,415		831		3,195		2,645
Net bookings excluding EUV (in units)		51		33		114		112
Average selling price of booked systems excluding EUV (EUR millions)		27.7		25.2		28.0		23.6
Number of payroll employees in FTEs		10,187		8,203		10,187		8,203
Number of temporary employees in FTEs		2,825		2,027		2,825		2,027

ASML—Summary U.S. GAAP Consolidated Balance Sheets ^1,2

	Sep 29,		Dec 31,
(in millions EUR)	2013		2012
ASSETS
Cash and cash equivalents		2,061.2		1,767.6
Short-term investments		662.5		930.0
Accounts receivable, net		626.2		605.3
Finance receivables, net		426.3		265.2
Current tax assets		26.8		57.1
Inventories, net		2,479.7		1,857.0
Deferred tax assets		158.6		103.7
Other assets		387.3		246.0
Total current assets		6,828.6		5,831.9
Finance receivables, net		17.6		38.6
Deferred tax assets		65.7		39.4
Other assets		287.3		311.6
Goodwill		1,949.4		149.2
Other intangible assets, net		745.4		9.9
Property, plant and equipment, net		1,173.2		1,029.9
Total non-current assets		4,238.6		1,578.6
Total assets		11,067.2		7,410.5
LIABILITIES AND SHAREHOLDERS’ EQUITY
Total current liabilities		2,758.3		2,086.3
Long-term debt		1,079.6		755.9
Deferred and other tax liabilities		363.7		88.3
Provisions		6.2		8.0
Accrued and other liabilities		256.3		405.1
Total non-current liabilities		1,705.8		1,257.3
Total liabilities		4,464.1		3,343.6
Total shareholders’ equity		6,603.1		4,066.9
Total liabilities and shareholders’ equity		11,067.2		7,410.5

ASML—Summary U.S. GAAP Consolidated Statements of Cash Flows ^1,2

	Three months ended,						Nine months ended,
(in millions EUR)	Sep 29, 2013			Sep 30, 2012			Sep 29, 2013			Sep 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net income		193.1			274.7			510.1			848.6
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization		67.9			36.7			161.2			143.1
Impairment		0.5			1.7			3.2			2.8
Loss on disposal of property, plant and equipment		0.5			0.5			1.1			2.0
Share-based payments		19.4			4.9			34.5			13.7
Allowance for doubtful receivables		0.5			0.5			1.2			0.8
Allowance for obsolete inventory		48.2			31.0			112.5			108.0
Deferred income taxes		(12.8	)		25.6			2.4			47.9
Changes in assets and liabilities		(209.9	)		113.7			(293.8	)		(207.9	)
Net cash provided by (used in) operating activities		107.4			489.3			532.4			959.0
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(55.3	)		(50.2	)		(133.1	)		(136.2	)
Purchase of intangible assets		—			—			(4.0	)		(3.3	)
Purchase of available for sale securities		(174.9	)		(440.0	)		(649.9	)		(1,290.0	)
Maturity of available for sale securities		270.7			250.0			957.4			250.0
Acquisition of subsidiaries (net of cash acquired)		—			—			(443.7	)		—
Net cash provided by (used in) investing activities		40.5			(240.2	)		(273.3	)		(1,179.5	)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividend paid		—			—			(216.1	)		(188.9	)
Purchase of shares		(51.6	)		(25.2	)		(136.3	)		(269.7	)
Net proceeds from issuance of shares		4.0			3,046.5			21.6			3,067.0
Net proceeds from issuance of bond		740.4			—			740.4			—
Repurchase of bond 4		(368.3	)		—			(368.3	)		—
Capital repayment		—			—			—			—
Repayment of debt		(1.2	)		(0.7	)		(2.9	)		(2.1	)
Tax benefit from share-based payments		1.9			1.5			1.9			1.6
Net cash provided by (used in) financing activities		325.2			3,022.1			40.3			2,607.9
Net cash flows		473.1			3,271.2			299.4			2,387.4
Effect of changes in exchange rates on cash		(4.2	)		(4.2	)		(5.8	)		(0.4	)
Net increase (decrease) in cash and cash equivalents		468.9			3,267.0			293.6			2,387.0

ASML—Quarterly Summary U.S. GAAP Consolidated Statements of Operations ^1,2

	Three months ended,
(in millions EUR, except per share data)	Sep 29, 2013			Jun 30, 2013			Mar 31, 2013			Dec 31, 2012			Sep 30, 2012
Net system sales		959.5			915.5			676.9			766.5			1,000.3
Net service and field option sales		358.7			271.2			215.2			256.6			228.5
Total net sales		1,318.2			1,186.7			892.1			1,023.1			1,228.8
Total cost of sales		(787.4	)		(704.5	)		(551.4	)		(602.9	)		(697.8	)
Gross profit		530.8			482.2			340.7			420.2			531.0
Other income		16.7			16.3			14.2			—			—
Research and development costs		(244.1	)		(200.0	)		(184.8	)		(155.4	)		(143.8	)
Selling, general and administrative costs		(91.2	)		(67.9	)		(62.6	)		(79.5	)		(69.7	)
Income from operations		212.2			230.6			107.5			185.3			317.5
Interest and other, net		(11.6	)		(6.0	)		(3.3	)		(3.4	)		(2.5	)
Income before income taxes		200.6			224.6			104.2			181.9			315.0
Benefit from (provision for) income taxes		(7.5	)		(3.8	)		(8.0	)		115.8			(40.3	)
Net income		193.1			220.8			96.2			297.7			274.7
Basic net income per ordinary share		0.44			0.52			0.24			0.66			0.65
Diluted net income per ordinary share 3		0.43			0.51			0.23			0.65			0.65
Weighted average number of ordinary shares used in computing per share amounts (in millions):
Basic		443.0			426.1			407.5			452.5			422.5
Diluted 3		447.1			430.4			410.6			455.4			425.7

ASML—Quarterly Summary Ratios and other data ^1,2

	Three months ended,
(in millions EUR, except otherwise indicated)	Sep 29, 2013		Jun 30, 2013		Mar 31, 2013		Dec 31, 2012			Sep 30, 2012
Gross profit as a percentage of net sales		40.3		40.6		38.2		41.1			43.2
Income from operations as a percentage of net sales		16.1		19.4		12.1		18.1			25.8
Net income as a percentage of net sales		14.7		18.6		10.8		29.1			22.4
Income taxes as a percentage of income before income taxes		3.7		1.7		7.6		(63.7	)		12.8
Shareholders’ equity as a percentage of total assets		59.7		62.6		54.8		54.9			65.2
Sales of systems (in units)		34		38		29		34			40
Average selling price of system sales (EUR millions)		28.2		24.1		23.3		22.5			25.0
Value of systems backlog excluding EUV (EUR millions)		1,838		1,395		1,266		1,214			1,340
Systems backlog excluding EUV (in units)		59		42		42		46			48
Average selling price of systems backlog excluding EUV (EUR millions)		31.1		33.2		30.1		26.4			27.9
Value of booked systems excluding EUV (EUR millions)		1,415		1,065		715		667			831
Net bookings excluding EUV (in units)		51		38		25		32			33
Average selling price of booked systems excluding EUV (EUR millions)		27.7		28.0		28.6		20.9			25.2
Number of payroll employees in FTEs		10,187		10,001		8,625		8,497			8,203
Number of temporary employees in FTEs		2,825		2,482		2,249		2,139			2,027

ASML—Quarterly Summary U.S. GAAP Consolidated Balance Sheets ^1,2

	Sep 29,		Jun 30,		Mar 31,		Dec 31,		Sep 30,
(in millions EUR)	2013		2013		2013		2012		2012
ASSETS
Cash and cash equivalents		2,061.2		1,592.3		1,780.1		1,767.6		5,118.8
Short-term investments		662.5		758.3		840.0		930.0		1,040.0
Accounts receivable, net		626.2		612.8		689.8		605.3		326.8
Finance receivables, net		426.3		252.4		300.8		265.2		221.6
Current tax assets		26.8		49.4		64.8		57.1		36.6
Inventories, net		2,479.7		2,359.0		2,005.8		1,857.0		1,920.0
Deferred tax assets		158.6		162.4		105.1		103.7		111.0
Other assets		387.3		292.3		278.6		246.0		235.0
Total current assets		6,828.6		6,078.9		6,065.0		5,831.9		9,009.8
Finance receivables, net		17.6		17.5		17.4		38.6		44.7
Deferred tax assets		65.7		52.5		40.3		39.4		38.3
Other assets		287.3		292.1		312.7		311.6		304.9
Goodwill		1,949.4		2,017.3		153.2		149.2		145.9
Other intangible assets, net		745.4		782.3		12.6		9.9		7.2
Property, plant and equipment, net		1,173.2		1,137.2		1,012.3		1,029.9		1,036.9
Total non-current assets		4,238.6		4,298.9		1,548.5		1,578.6		1,577.9
Total assets		11,067.2		10,377.8		7,613.5		7,410.5		10,587.7
LIABILITIES AND SHAREHOLDERS’ EQUITY
Total current liabilities		2,758.3		2,489.4		2,346.4		2,086.3		2,301.8
Long-term debt		1,079.6		735.6		746.6		755.9		747.3
Deferred and other tax liabilities		363.7		385.0		92.1		88.3		215.2
Provisions		6.2		6.9		6.6		8.0		8.7
Accrued and other liabilities		256.3		262.9		249.7		405.1		409.0
Total non-current liabilities		1,705.8		1,390.4		1,095.0		1,257.3		1,380.2
Total liabilities		4,464.1		3,879.8		3,441.4		3,343.6		3,682.0
Total shareholders’ equity		6,603.1		6,498.0		4,172.1		4,066.9		6,905.7
Total liabilities and shareholders’ equity		11,067.2		10,377.8		7,613.5		7,410.5		10,587.7

ASML—Quarterly Summary U.S. GAAP Consolidated Statements of Cash Flows ^1,2

	Three months ended,
(in millions EUR)	Sep 29, 2013			Jun 30, 2013			Mar 31, 2013			Dec 31, 2012			Sep 30, 2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net income		193.1			220.8			96.2			297.7			274.7
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization		67.9			48.8			44.5			43.5			36.7
Impairment		0.5			2.6			0.1			0.5			1.7
Loss on disposal of property, plant and equipment		0.5			0.5			0.1			0.2			0.5
Share-based payments		19.4			9.4			5.7			5.0			4.9
Allowance for doubtful receivables		0.5			0.4			0.3			(0.3	)		0.5
Allowance for obsolete inventory		48.2			33.9			30.4			22.9			31.0
Deferred income taxes		(12.8	)		14.9			0.3			(120.3	)		25.6
Changes in assets and liabilities		(209.9	)		150.0			(233.9	)		(504.7	)		113.7
Net cash provided by (used in) operating activities		107.4			481.3			(56.3	)		(255.5	)		489.3
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(55.3	)		(50.5	)		(27.3	)		(35.7	)		(50.2	)
Purchase of intangible assets		—			—			(4.0	)		(4.3	)		—
Purchase of available for sale securities		(174.9	)		(125.0	)		(350.0	)		(90.0	)		(440.0	)
Maturity of available for sale securities		270.7			246.7			440.0			200.0			250.0
Acquisition of subsidiaries (net of cash acquired)		—			(443.7	)		—			(10.3	)		—
Net cash provided by (used in) investing activities		40.5			(372.5	)		58.7			59.7			(240.2	)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividend paid		—			(216.1	)		—			—			—
Purchase of shares		(51.6	)		(84.7	)		—			(265.7	)		(25.2	)
Net proceeds from issuance of shares		4.0			7.2			10.4			840.7			3,046.5
Net proceeds from issuance of bond		740.4			—			—			—			—
Repurchase of bond 4		(368.3	)		—			—			—			—
Capital repayment		—			—			—			(3,728.3	)		—
Repayment of debt		(1.2	)		(0.9	)		(0.8	)		(0.8	)		(0.7	)
Tax benefit from share-based payments		1.9			—			—			0.6			1.5
Net cash provided by (used in) financing activities		325.2			(294.5	)		9.6			(3,153.5	)		3,022.1
Net cash flows		473.1			(185.7	)		12.0			(3,349.3	)		3,271.2
Effect of changes in exchange rates on cash		(4.2	)		(2.1	)		0.5			(1.9	)		(4.2	)
Net increase (decrease) in cash and cash equivalents		468.9			(187.8	)		12.5			(3,351.2	)		3,267.0

Notes to the Summary U.S. GAAP Consolidated Financial Statements

Basis of Presentation

The accompanying consolidated financial statements are stated in millions of euros (‘EUR’) unless otherwise indicated. ASML follows accounting principles generally accepted in the United States of America (“U.S. GAAP”). On May 30, 2013, we acquired 100% of the issued share capital of Cymer Inc., financial information presented in the Consolidated Financial Statements include Cymer Inc. as of that date. Further disclosures, as required under U.S. GAAP in annual reports, are not included in the summary consolidated financial statements.

Use of estimates

The preparation of our consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities on the balance sheet dates, and the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates.

Principles of consolidation

The consolidated financial statements include the financial statements of ASML Holding N.V. and all of its subsidiaries and the variable interest entities in which ASML is the primary beneficiary (referred to as “ASML”). All intercompany profits, balances and transactions have been eliminated in the consolidation. Subsidiaries are all entities over which ASML has the power to govern the financial and operating policies generally accompanying a shareholding of more than one-half of the voting rights.

Revenue recognition

In general, ASML recognizes revenue when all four revenue recognition criteria are met: persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; seller’s price to buyer is fixed or determinable; and collectability is reasonably assured. At ASML this policy generally results in revenue recognition from the sale of a system upon shipment. The revenue from the installation of a system is generally recognized upon completion of that installation at the customer site. Each system undergoes, prior to shipment, a “Factory Acceptance Test” in ASML’s cleanroom facilities, effectively replicating the operating conditions that will be present on the customer’s site, in order to verify whether the system will meet its standard specifications and any additional technical and performance criteria agreed with the customer, if any. A system is shipped, and revenue is recognized, only after all specifications are met and customer sign-off is received or waived. In case not all specifications are met and the remaining performance obligation is not essential to the functionality of the system but is substantive rather than inconsequential or perfunctory, a portion of the sales price is deferred. Although each system’s performance is re-tested upon installation at the customer’s site, ASML has never failed to successfully complete installation of a system at a customer’s premises.

The main portion of ASML’s revenue is derived from contractual arrangements with our customers that have multiple deliverables, which mainly include the sale of our systems, installation and training services and prepaid extended and enhanced (optic) warranty contracts. For each of the specified deliverables ASML determines the selling price by using either vendor specific objective evidence (‘VSOE’), third party evidence (‘TPE’) or by best estimate of the selling price (‘BESP’). When we are unable to establish relative selling price using VSOE or TPE, ASML uses BESP in its allocation of arrangement consideration. The total arrangement consideration is allocated at inception of the arrangement to all deliverables on the basis of their relative selling price. The revenue relating to the undelivered elements of the arrangements is deferred at their relative selling prices until delivery of these elements. Revenue from installation and training services is recognized when the services are completed. Revenue from prepaid extended and enhanced (optic) warranty contracts is recognized over the term of the contract.

Foreign currency risk management

Our sales are predominately denominated in euros. Exceptions may occur on a customer by customer basis. Our cost of sales and other expenses are mainly dominated in euros, to a certain extent in U.S. dollar and Japanese yen and to a limited extent in other currencies. Therefore, we are exposed to foreign currency exchange risk.

It is our policy to hedge material transaction exposures, such as forecasted sales and purchase transactions, and material net remeasurement exposures, such as accounts receivable and payable. We hedge these exposures through the use of foreign exchange contracts.

ASML—Reconciliation U.S. GAAP—IFRS ^1,2

Net income	Three months ended,					Nine months ended,
	Sep 29,		Sep 30,			Sep 29,			Sep 30,
(in millions EUR)	2013		2012			2013			2012
Net income based on U.S. GAAP		193.1		274.7			510.1			848.6
Development expenditures (see Note 1)		50.7		49.0			160.6			123.7
Share-based payments (see Note 2)		1.5		0.2			2.2			0.4
Income taxes (see Note 3)		2.8		(0.9	)		(10.1	)		2.0
Reversal of write-downs (see Note 4)		—		(0.4	)		—			6.8
Net income based on IFRS		248.1		322.6			662.8			981.5

Shareholders’ equity	Sep 29,		Jun 30,		Mar 31,		Dec 31,		Sep 30,
(in millions EUR)	2013		2013		2013		2012		2012
Shareholders’ equity based on U.S. GAAP		6,603.1		6,498.0		4,172.1		4,066.9		6,905.7
Development expenditures (see Note 1)		555.7		507.3		456.1		396.8		356.6
Share-based payments (see Note 2)		27.9		27.1		4.2		4.1		4.1
Income taxes (see Note 3)		18.0		18.3		32.1		30.4		35.0
Reversal of write-downs (see Note 4)		—		—		—		—		14.0
Equity based on IFRS		7,204.7		7,050.7		4,664.5		4,498.2		7,315.4

Notes to the reconciliation from U.S. GAAP to IFRS

Note 1 Development expenditures

Under U.S. GAAP, ASML applies ASC 730, “Research and Development”. In accordance with ASC 730, ASML charges costs relating to research and development to operating expense as incurred.

Under IFRS, ASML applies IAS 38, “Intangible Assets”. In accordance with IAS 38, ASML capitalizes certain development expenditures that are amortized over the expected useful life of the related product generally ranging between one and three years. Amortization starts when the developed product is ready for volume production.

Note 2 Share-based Payments

Under U.S. GAAP, ASML applies ASC 718 “Compensation- Stock Compensation” which requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant-date fair value of those instruments. ASC 718’s general principle is that a deferred tax asset is established as we recognize compensation costs for commercial purposes for awards that are expected to result in a tax deduction under existing tax law. Under U.S. GAAP, the deferred tax recorded on share-based compensation is computed on the basis of the expense recognized in the financial statements. Therefore, changes in ASML’s share price do not affect the deferred tax asset recorded in our financial statements.

Under IFRS, ASML applies IFRS 2, “Share-based Payments”. In accordance with IFRS 2, ASML records as an expense the fair value of its share-based payments with respect to stock options and stock granted to its employees after November 7, 2002. Under IFRS, at period end a deferred tax asset is computed on the basis of the tax deduction for the share-based payments under the applicable tax law and is recognized to the extent it is probable that future taxable profit will be available against which these deductible temporary differences will be utilized. Therefore, changes in ASML’s share price do affect the deferred tax asset at period-end and result in adjustments to the deferred tax asset.

Note 3 Income taxes

Under U.S. GAAP, the elimination of unrealized net income from intercompany transactions that are eliminated from the carrying amount of assets in consolidation give rise to a temporary difference for which prepaid taxes must be recognized in consolidation. Contrary to IFRS, the prepaid taxes under U.S. GAAP are calculated based on the tax rate applicable in the seller’s rather than the purchaser’s tax jurisdiction.

Under IFRS, ASML applies IAS 12, “Income Taxes” beginning from January 1, 2005. In accordance with IAS 12 unrealized net income resulting from intercompany transactions that are eliminated from the carrying amount of assets in consolidation give rise to a temporary difference for which deferred taxes must be recognized in consolidation. The deferred taxes are calculated based on the tax rate applicable in the purchaser’s tax jurisdiction.

Note 4 Reversal of write-downs

Under U.S. GAAP, ASML applies ASC 330 “Inventory”. In accordance with ASC 330 reversal of a write-down is prohibited as a write-down creates a new cost basis.

Under IFRS, ASML applies IAS 2 (revised), “Inventories”. In accordance with IAS 2, reversal of a prior period write-down as a result of a subsequent increase in value of inventory should be recognized in the period in which the value increase occurs.

“Safe Harbor” Statement under the US Private Securities Litigation Reform Act of 1995: the matters discussed in this document may include forward-looking statements, including statements made about our outlook, expected sales levels, realization of systems backlog, IC unit demand, expected financial results, gross margin and expenses, expected impact and adjustments relating to the Cymer acquisition (including purchase price allocation adjustments), the number of EUV systems expected to be shipped and recognized in revenue and timing of shipments, dividend policy and intention to repurchase shares. These forward looking statements are subject to risks and uncertainties including, but not limited to: economic conditions, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), including the impact of general economic conditions on consumer confidence and demand for our customers’ products, competitive products and pricing, the impact of manufacturing efficiencies and capacity constraints, the continuing success of technology advances and the related pace of new product development and customer acceptance of new products, our ability to enforce patents and protect intellectual property rights, the risk of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, changes in exchange rates, available cash, distributable reserves for dividend payments and share repurchases, our ability to successfully integrate Cymer and the amounts of adjustments ultimately recognized in connection with the Cymer acquisition, and other risks indicated in the risk factors included in ASML’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission.

¹  These financial statements are unaudited.

²  Numbers have been rounded.

³  The calculation of diluted net income per ordinary share assumes the exercise of options issued under ASML stock option plans and the issuance of shares under ASML share plans for periods in which exercises or issuances would have a dilutive effect. The calculation of diluted net income per ordinary share does not assume exercise of such options or issuance of shares when such exercises or issuance would be anti-dilutive.

⁴  The repurchase of bond consists of EUR 417.4 million cash payments to the bond holders offset by cash received as a result of unwinding the relating interest rate swap for an amount of EUR 49.1 million.

EX-99.4

Exhibit 99.4

ASML—Summary IFRS Consolidated Statement of Profit or Loss ^1,2

	Three months ended,						Nine months ended,
(in millions EUR)	Sep 29, 2013			Sep 30, 2012			Sep 29, 2013			Sep 30, 2012
Net system sales		959.5			1,000.3			2,551.9			3,035.1
Net service and field option sales		358.7			228.5			845.1			673.3
Total net sales		1,318.2			1,228.8			3,397.0			3,708.4
Total cost of sales		(808.3	)		(724.6	)		(2,104.0	)		(2,193.6	)
Gross profit		509.9			504.2			1,293.0			1,514.8
Other income		16.7			—			47.2			—
Research and development costs		(162.3	)		(60.4	)		(380.7	)		(210.6	)
Selling, general and administrative costs		(90.1	)		(70.4	)		(222.0	)		(177.6	)
Operating income		274.2			373.4			737.5			1,126.6
Interest and other, net		(9.8	)		(2.9	)		(16.7	)		(4.0	)
Income before income taxes		264.4			370.5			720.8			1,122.6
Benefit from (provision for) income taxes		(16.3	)		(47.9	)		(58.0	)		(141.1	)
Net income		248.1			322.6			662.8			981.5

ASML—Summary IFRS Consolidated Statement of Financial Position ^1,2

	Sep 29,		Dec 31,
(in millions EUR)	2013		2012
ASSETS
Property, plant and equipment		1,173.2		1,029.9
Goodwill		1,977.9		158.1
Other intangible assets		1,386.8		460.9
Deferred tax assets		281.7		188.6
Finance receivables		17.6		38.6
Derivative financial instruments		21.8		101.7
Other assets		261.6		206.9
Total non-current assets		5,120.6		2,184.7
Inventories		2,479.7		1,857.0
Current tax assets		26.8		57.1
Derivative financial instruments		56.2		50.1
Finance receivables		426.3		265.2
Accounts receivable		626.2		605.3
Other assets		278.0		166.0
Short-term investments		662.5		930.0
Cash and cash equivalents		2,061.2		1,767.6
Total current assets		6,616.9		5,698.3
Total assets		11,737.5		7,883.0
EQUITY AND LIABILITIES
Equity		7,204.7		4,498.2
Long-term debt		1,075.8		752.9
Derivative financial instruments		2.7		4.0
Deferred and other tax liabilities		438.4		132.8
Provisions		6.2		8.0
Accrued and other liabilities		253.6		401.1
Total non-current liabilities		1,776.7		1,298.8
Provisions		2.3		2.3
Derivative financial instruments		8.5		6.9
Current portion of long-term debt		3.8		3.6
Current and other tax liabilities		17.7		10.7
Accrued and other liabilities		2,001.0		1,873.5
Accounts payable		722.8		189.0
Total current liabilities		2,756.1		2,086.0
Total equity and liabilities		11,737.5		7,883.0

ASML—Summary IFRS Consolidated Statement of Cash Flows ^1,2

	Three months ended,						Nine months ended,
	Sep 29,			Sep 30,			Sep 29,			Sep 30,
(in millions EUR)	2013			2012			2013			2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net income		248.1			322.6			662.8			981.5
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization		86.2			62.6			218.0			220.0
Impairment		0.5			1.7			3.2			2.8
Loss on disposal of property, plant and equipment		0.5			0.5			1.1			2.0
Share-based payments		17.2			4.9			32.3			13.7
Allowance for doubtful receivables		0.5			0.5			1.2			0.8
Allowance for obsolete inventory		48.2			18.4			112.5			80.1
Deferred income taxes		(27.6	)		36.6			24.8			71.4
Changes in assets and liabilities		(182.1	)		126.4			(268.2	)		(188.5	)
Net cash provided by (used in) operating activities		191.5			574.2			787.7			1,183.8
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(55.3	)		(50.2	)		(133.1	)		(136.2	)
Purchase of intangible assets		(82.2	)		(83.4	)		(257.4	)		(226.5	)
Purchase of available for sale securities		(174.9	)		(440.0	)		(649.9	)		(1,290.0	)
Maturity of available for sale securities		270.7			250.0			957.4			250.0
Acquisition of subsidiaries (net of cash acquired)		—			—			(443.7	)		—
Net cash provided by (used in) investing activities		(41.7	)		(323.6	)		(526.7	)		(1,402.7	)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividend paid		—			—			(216.1	)		(188.9	)
Purchase of shares		(51.6	)		(25.2	)		(136.3	)		(269.7	)
Net proceeds from issuance of shares		4.0			3,046.5			21.6			3,067.0
Net proceeds from issuance of bond		740.4			—			740.4			—
Repurchase of bond 3		(368.3	)		—			(368.3	)		—
Capital repayment		—			—			—			—
Repayment of debt		(1.2	)		(0.7	)		(2.9	)		(2.1	)
Net cash provided by (used in) financing activities		323.3			3,020.6			38.4			2,606.3
Net cash flows		473.1			3,271.2			299.4			2,387.4
Effect of changes in exchange rates on cash		(4.2	)		(4.2	)		(5.8	)		(0.4	)
Net increase (decrease) in cash and cash equivalents		468.9			3,267.0			293.6			2,387.0

ASML—Quarterly Summary IFRS Consolidated Statement of Profit or Loss ^1,2

				Three months ended,
	Sep 29,			Jun 30,			Mar 31,			Dec 31,			Sep 30,
(in millions EUR)	2013			2013			2013			2012			2012
Net system sales		959.5			915.5			676.9			766.5			1,000.3
Net service and field option sales		358.7			271.2			215.2			256.6			228.5
Total net sales		1,318.2			1,186.7			892.1			1,023.1			1,228.8
Total cost of sales		(808.3	)		(724.9	)		(570.8	)		(642.1	)		(724.6	)
Gross profit		509.9			461.8			321.3			381.0			504.2
Other income		16.7			16.3			14.2			—			—
Research and development costs		(162.3	)		(116.7	)		(101.7	)		(87.5	)		(60.4	)
Selling, general and administrative costs		(90.1	)		(69.2	)		(62.7	)		(78.9	)		(70.4	)
Operating income		274.2			292.2			171.1			214.6			373.4
Interest and other, net		(9.8	)		(6.7	)		(0.2	)		0.7			(2.9	)
Income before income taxes		264.4			285.5			170.9			215.3			370.5
Benefit from (provision for) income taxes		(16.3	)		(26.5	)		(15.2	)		105.5			(47.9	)
Net income		248.1			259.0			155.7			320.8			322.6

ASML—Quarterly Summary IFRS Consolidated Statement of Financial Position ^1,2

	Sep 29,		Jun 30,		Mar 31,		Dec 31,		Sep 30,
(in millions EUR)	2013		2013		2013		2012		2012
ASSETS
Property, plant and equipment		1,173.2		1,137.2		1,012.3		1,029.9		1,036.9
Goodwill		1,977.9		2,046.8		162.3		158.1		154.9
Other intangible assets		1,386.8		1,364.5		533.2		460.9		411.4
Deferred tax assets		281.7		236.7		189.5		188.6		195.3
Finance receivables		17.6		17.5		17.4		38.6		44.7
Derivative financial instruments		21.8		65.9		102.1		101.7		94.0
Other assets		261.6		223.6		207.8		206.9		207.8
Total non-current assets		5,120.6		5,092.2		2,224.6		2,184.7		2,145.0
Inventories		2,479.7		2,359.0		2,005.8		1,857.0		1,935.8
Current tax assets		26.8		49.4		64.8		57.1		36.6
Derivative financial instruments		56.2		35.0		32.6		50.1		41.9
Finance receivables		426.3		252.4		300.8		265.2		221.6
Accounts receivable		626.2		612.8		689.8		605.3		326.8
Other assets		278.0		232.5		215.2		166.0		167.5
Short-term investments		662.5		758.3		840.0		930.0		1,040.0
Cash and cash equivalents		2,061.2		1,592.3		1,780.1		1,767.6		5,118.8
Total current assets		6,616.9		5,891.7		5,929.1		5,698.3		8,889.0
Total assets		11,737.5		10,983.9		8,153.7		7,883.0		11,034.0
EQUITY AND LIABILITIES
Equity		7,204.7		7,050.7		4,664.5		4,498.2		7,315.4
Long-term debt		1,075.8		732.9		743.8		752.9		744.2
Derivative financial instruments		2.7		2.9		11.8		4.0		3.7
Deferred and other tax liabilities		438.4		441.3		143.1		132.8		255.0
Provisions		6.2		6.9		6.6		8.0		8.7
Accrued and other liabilities		253.6		260.0		237.9		401.1		405.3
Total non-current liabilities		1,776.7		1,444.0		1,143.2		1,298.8		1,416.9
Provisions		2.3		2.4		3.3		2.3		2.3
Derivative financial instruments		8.5		9.1		3.4		6.9		7.2
Current portion of long-term debt		3.8		3.8		3.6		3.6		2.6
Current and other tax liabilities		17.7		1.8		18.2		10.7		11.2
Accrued and other liabilities		2,001.0		1,960.1		1,895.2		1,873.5		1,885.5
Accounts payable		722.8		512.0		422.3		189.0		392.9
Total current liabilities		2,756.1		2,489.2		2,346.0		2,086.0		2,301.7
Total equity and liabilities		11,737.5		10,983.9		8,153.7		7,883.0		11,034.0

ASML—Quarterly Summary IFRS Consolidated Statement of Cash Flows ^1,2

				Three months ended,
	Sep 29,			Jun 30,			Mar 31,			Dec 31,			Sep 30,
(in millions EUR)	2013			2013			2013			2012			2012
CASH FLOWS FROM OPERATING ACTIVITIES
Net income		248.1			259.0			155.7			320.8			322.6
Adjustments to reconcile net income to net cash flows from operating activities:
Depreciation and amortization		86.2			68.8			63.0			65.9			62.6
Impairment		0.5			2.6			0.1			0.5			1.7
Loss on disposal of property, plant and equipment		0.5			0.5			0.1			0.2			0.5
Share-based payments		17.2			9.4			5.7			5.0			4.9
Allowance for doubtful receivables		0.5			0.4			0.3			(0.3	)		0.5
Allowance for obsolete inventory		48.2			33.9			30.4			38.7			18.4
Deferred income taxes		(27.6	)		45.5			6.9			(113.1	)		36.6
Changes in assets and liabilities		(182.1	)		144.2			(230.3	)		(502.2	)		126.4
Net cash provided by (used in) operating activities		191.5			564.3			31.9			(184.5	)		574.2
CASH FLOWS FROM INVESTING ACTIVITIES
Purchase of property, plant and equipment		(55.3	)		(50.5	)		(27.3	)		(35.7	)		(50.2	)
Purchase of intangible assets		(82.2	)		(83.0	)		(92.2	)		(74.7	)		(83.4	)
Purchase of available for sale securities		(174.9	)		(125.0	)		(350.0	)		(90.0	)		(440.0	)
Maturity of available for sale securities		270.7			246.7			440.0			200.0			250.0
Acquisition of subsidiaries (net of cash acquired)		—			(443.7	)		—			(10.3	)		—
Net cash provided by (used in) investing activities		(41.7	)		(455.5	)		(29.5	)		(10.7	)		(323.6	)
CASH FLOWS FROM FINANCING ACTIVITIES
Dividend paid		—			(216.1	)		—			—			—
Purchase of shares		(51.6	)		(84.7	)		—			(265.7	)		(25.2	)
Net proceeds from issuance of shares		4.0			7.2			10.4			840.7			3,046.5
Net proceeds from issuance of bond		740.4			—			—			—			—
Repurchase of bond 3		(368.3	)		—			—			—			—
Capital repayment		—			—			—			(3,728.3	)		—
Repayment of debt		(1.2	)		(0.9	)		(0.8	)		(0.8	)		(0.7	)
Net cash provided by (used in) financing activities		323.3			(294.5	)		9.6			(3,154.1	)		3,020.6
Net cash flows		473.1			(185.7	)		12.0			(3,349.3	)		3,271.2
Effect of changes in exchange rates on cash		(4.2	)		(2.1	)		0.5			(1.9	)		(4.2	)
Net increase (decrease) in cash and cash equivalents		468.9			(187.8	)		12.5			(3,351.2	)		3,267.0

Notes to the Summary IFRS Consolidated Financial Statements

Basis of Presentation

The accompanying consolidated financial statements are stated in millions of euros (‘EUR’) unless otherwise indicated. ASML has prepared the accompanying summary consolidated financial statements in accordance with International Financial Reporting Standards (“IFRS”) as adopted by the EU – accounting principles generally accepted in the Netherlands for companies quoted on Euronext Amsterdam. On May 30, 2013, we acquired 100% of the issued share capital of Cymer Inc., financial information presented in the Consolidated Financial Statements include Cymer Inc. as of that date. Further disclosures, as required under IFRS in annual reports and interim reporting (IAS 34), are not included in the summary consolidated financial statements.

For internal and external reporting purposes, we apply accounting principles generally accepted in the United States of America (“U.S. GAAP”). U.S. GAAP is our primary accounting standard for the setting of financial and operational performance targets.

Use of estimates

The preparation of our consolidated financial statements in conformity with IFRS as adopted by the EU requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities on the dates of the statement of financial position and the reported amounts of revenue and expenses during the reported periods. Actual results could differ from those estimates.

Basis of consolidation

The consolidated financial statements include the financial statements of ASML Holding N.V. and its subsidiaries and the special purpose entities over which ASML has control (referred to as “ASML”). All intercompany profits, balances and transactions have been eliminated in the consolidation. Subsidiaries are all entities over which ASML has the power to govern the financial and operating policies generally accompanying a shareholding of more than one-half of the voting rights.

Revenue recognition

In general, we recognize the revenue from the sale of a system upon shipment and the revenue from the installation of a system upon completion of that installation at the customer site. Each system undergoes, prior to shipment, a “Factory Acceptance Test” in ASML’s cleanroom facilities, effectively replicating the operating conditions that will be present on the customer’s site, in order to verify whether the system will meet its standard specifications and any additional technical and performance criteria agreed with the customer, if any. A system is shipped, and revenue is recognized, only after all specifications are met and customer sign-off is received or waived. In case not all specifications are met and the remaining performance obligation is not essential to the functionality of the system but is substantive rather than inconsequential or perfunctory, a portion of the sales price is deferred. Although each system’s performance is re-tested upon installation at the customer’s site, we have never failed to successfully complete installation of a system at a customer’s premises.

The main portion of our revenue is derived from contractual arrangements with our customers that have multiple deliverables, which mainly include the sale of our systems, installation and training services and prepaid extended and enhanced (optic) warranty contracts. The revenue relating to the undelivered elements of the arrangements is deferred until delivery of these elements. Revenue from installation and training services is recognized when the services are completed. Revenue from prepaid extended and enhanced (optic) warranty contracts is recognized over the term of the contract.

Foreign currency risk management

Our sales are predominately denominated in euros. Exceptions may occur on a customer by customer basis. Our cost of sales and other expenses are mainly dominated in euros, to a certain extent in U.S. dollar and

Japanese yen and to a limited extent in other currencies. Therefore, we are exposed to foreign currency exchange risk.

It is our policy to hedge material transaction exposures, such as forecasted sales and purchase transactions, and material net remeasurement exposures, such as accounts receivable and payable. We hedge these exposures through the use of foreign exchange contracts.

ASML—Reconciliation U.S. GAAP – IFRS ^1,2

Net income	Three months ended,					Nine months ended,
	Sep 29,		Sep 30,			Sep 29,			Sep 30,
(in millions EUR)	2013		2012			2013			2012
Net income based on U.S. GAAP		193.1		274.7			510.1			848.6
Development expenditures (see Note 1)		50.7		49.0			160.6			123.7
Share-based payments (see Note 2)		1.5		0.2			2.2			0.4
Income taxes (see Note 3)		2.8		(0.9	)		(10.1	)		2.0
Reversal of write-downs (see Note 4)		—		(0.4	)		—			6.8
Net income based on IFRS		248.1		322.6			662.8			981.5

Shareholders’ equity	Sep 30,		Jun 30,		Mar 31,		Dec 31,		Sep 30,
(in millions EUR)	2013		2013		2013		2012		2012
Shareholders’ equity based on U.S. GAAP		6,603.1		6,498.0		4,172.1		4,066.9		6,905.7
Development expenditures (see Note 1)		555.7		507.3		456.1		396.8		356.6
Share-based payments (see Note 2)		27.9		27.1		4.2		4.1		4.1
Income taxes (see Note 3)		18.0		18.3		32.1		30.4		35.0
Reversal of write-downs (see Note 4)		—		—		—		—		14.0
Equity based on IFRS		7,204.7		7,050.7		4,664.5		4,498.2		7,315.4

Notes to the reconciliation from U.S. GAAP to IFRS

Note 1 Development expenditures

Under U.S. GAAP, ASML applies ASC 730, “Research and Development”. In accordance with ASC 730, ASML charges costs relating to research and development to operating expense as incurred.

Under IFRS, ASML applies IAS 38, “Intangible Assets”. In accordance with IAS 38, ASML capitalizes certain development expenditures that are amortized over the expected useful life of the related product generally ranging between one and three years. Amortization starts when the developed product is ready for volume production.

Note 2 Share-based Payments

Under U.S. GAAP, ASML applies ASC 718 “Compensation- Stock Compensation” which requires companies to recognize the cost of employee services received in exchange for awards of equity instruments based upon the grant-date fair value of those instruments. ASC 718’s general principle is that a deferred tax asset is established as we recognize compensation costs for commercial purposes for awards that are expected to result in a tax deduction under existing tax law. Under U.S. GAAP, the deferred tax recorded on share-based compensation is computed on the basis of the expense recognized in the financial statements. Therefore, changes in ASML’s share price do not affect the deferred tax asset recorded in our financial statements.

Under IFRS, ASML applies IFRS 2, “Share-based Payments”. In accordance with IFRS 2, ASML records as an expense the fair value of its share-based payments with respect to stock options and stock granted to its employees after November 7, 2002. Under IFRS, at period end a deferred tax asset is computed on the basis of the tax deduction for the share-based payments under the applicable tax law and is recognized to the extent it is probable that future taxable profit will be available against which these deductible temporary differences will be utilized. Therefore, changes in ASML’s share price do affect the deferred tax asset at period-end and result in adjustments to the deferred tax asset.

Note 3 Income taxes

Under U.S. GAAP, the elimination of unrealized net income from intercompany transactions that are eliminated from the carrying amount of assets in consolidation give rise to a temporary difference for which prepaid taxes must be recognized in consolidation. Contrary to IFRS, the prepaid taxes under U.S. GAAP are calculated based on the tax rate applicable in the seller’s rather than the purchaser’s tax jurisdiction.

Under IFRS, ASML applies IAS 12, “Income Taxes” beginning from January 1, 2005. In accordance with IAS 12 unrealized net income resulting from intercompany transactions that are eliminated from the carrying amount of assets in consolidation give rise to a temporary difference for which deferred taxes must be recognized in consolidation. The deferred taxes are calculated based on the tax rate applicable in the purchaser’s tax jurisdiction.

Note 4 Reversal of write-downs

Under U.S. GAAP, ASML applies ASC 330 “Inventory”. In accordance with ASC 330 reversal of a write-down is prohibited as a write-down creates a new cost basis.

Under IFRS, ASML applies IAS 2 (revised), “Inventories”. In accordance with IAS 2, reversal of a prior period write-down as a result of a subsequent increase in value of inventory should be recognized in the period in which the value increase occurs.

“Safe Harbor” Statement under the US Private Securities Litigation Reform Act of 1995: the matters discussed in this document may include forward-looking statements, including statements made about our outlook, expected sales levels, realization of systems backlog, IC unit demand, expected financial results, gross margin and expenses, expected impact and adjustments relating to the Cymer acquisition (including purchase price allocation adjustments), the number of EUV systems expected to be shipped and recognized in revenue and timing of shipments, dividend policy and intention to repurchase shares. These forward looking statements are subject to risks and uncertainties including, but not limited to: economic conditions, product demand and semiconductor equipment industry capacity, worldwide demand and manufacturing capacity utilization for semiconductors (the principal product of our customer base), including the impact of general economic conditions on consumer confidence and demand for our customers’ products, competitive products and pricing, the impact of manufacturing efficiencies and capacity constraints, the continuing success of technology advances and the related pace of new product development and customer acceptance of new products, our ability to enforce patents and protect intellectual property rights, the risk of intellectual property litigation, availability of raw materials and critical manufacturing equipment, trade environment, changes in exchange rates, available cash, distributable reserves for dividend payments and share repurchases, our ability to successfully integrate Cymer and the amounts of adjustments ultimately recognized in connection with the Cymer acquisition, and other risks indicated in the risk factors included in ASML’s Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission.

¹  These financial statements are unaudited.

²  Numbers have been rounded.

³  The repurchase of bond consists of EUR 417.4 million cash payments to the bond holders offset by cash received as a result of unwinding the relating interest rate swap for an amount of EUR 49.1 million.